iShares MSCI Indonesia ETF vs Intuitive Surgical, Inc. — how do they compare? iShares MSCI Indonesia ETF trades at $12.22, while Intuitive Surgical, Inc. trades at $400.23 (market cap $137.76B). Which is the better fit depends on your goals.
| EIDO | ISRG | |
|---|---|---|
52-Week High | $19.22 | $592.85 |
52-Week Low | $10.80 | $379.50 |
Market Cap | — | $137.76B |
Sector | — | Health |
Enterprise Value | — | $133.24B |
Signals from Pluang's Aura AI — not financial advice
The iShares MSCI Indonesia ETF (EIDO) trades at $12.20, up 1.08% on the day, while technical indicators signal a bearish trend with moving averages and overall signals in sell territory. Recent news highlights Indonesia's economic initiatives, including a $15 billion AI-integrated free-meal program and central bank rate hikes to support the rupiah, which directly impacts this country-focused ETF. The fund's dividend was reported to have dropped 27% in 2025, raising questions about underlying asset performance.
The outlook for EIDO is tied to Indonesia's macroeconomic stability and government policy execution. Investment opportunity lies in exposure to Indonesia's growth initiatives, but risks include currency volatility from Bank Indonesia's defensive actions, geopolitical pressures on emerging markets, and the ETF's high-yield but potentially unstable dividend profile.
Intuitive Surgical (ISRG) trades at $379.50, down 6.78% amid broader market pressure, yet maintains strong fundamentals with 28.15% net margins and consistent earnings beats. The stock faces technical headwinds with bearish moving averages but shows oversold RSI conditions. Recent news highlights competitive pressures but also strong da Vinci 5 adoption and upcoming Q2 earnings on July 16, where analysts expect another beat. Revenue growth remains robust at $10.06B for 2025, up from $8.4B in 2024.
Despite near-term volatility, ISRG's leadership in robotic surgery and analyst consensus price target of $552.36 suggest significant upside. Key risks include intensifying global competition and margin pressures, but the company's innovation pipeline and expanding procedure volumes support long-term growth. Institutional sentiment remains positive with 69.6% buy ratings, positioning ISRG as a compelling recovery candidate post-earnings.
Trailing returns across standard periods
Latest headlines on both assets
The fund generally will invest at least 80% of its assets in the component securities of the underlying index and in investments that have economic characteristics that are substantially identical to the component securities of the underlying index. The index is a free float-adjusted market capitalization-weighted index that is designed to measure the performance of the large-, mid- and small-capitalization segments of the equity market in Indonesia. The fund is non-diversified.
Read more on EIDO →Intuitive Surgical develops, produces, and markets a robotic system for assisting minimally invasive surgery. It also provides the instrumentation, disposable accessories, and warranty services for the system. The company has placed nearly 7,000 da Vinci systems in hospitals worldwide, with more than 4,000 installations in the United States and a growing number in emerging markets.
Read more on ISRG →